Heart Failure and Hypertension

Drawing of heart diagram with parts of the heart labeled with letters
Comprehensive Solutions for Heart Failure Management

Breakthrough technologies with proven clinical outcomes

Approximately 26 million people live with HF worldwide,1 and the estimated global cost is $108 billion annually.2 With the complexity and rise of heart failure, the Heart Failure Association of the European Society of Cardiology aims to make the prevention and management of heart failure a global health priority.

At Abbott, we dedicate our efforts to providing you with the broadest scope of innovative and outcome-driven solutions to manage the clinical and economic burden of heart failure and hypertension. The benefits of frequent insight and early intervention that our technologies can give you are matched only by our ability to increase efficacy while decreasing the economic cost associated with cardiovascular care.



Patient who received MultiPoint™ pacing playing with grandson in a meadow

Heart Failure Management Portfolio

Abbott innovates and challenges the status quo, offering game-changing heart failure technologies to help better manage the economic and treatment challenges associated with heart failure. Our results include innovative and effective quadripolar technology, MultiPoint™ pacing, patient management technologies, the HeartMate 3™ left ventricular assist system and the CentriMag™ acute circulatory assist system.

Related Portfolios

Learn about our other advanced portfolio solutions designed to improve the treatment of heart failure and hypertension while reducing costs for all.

Hypertension Portfolio

Our cutting-edge diagnostic and therapeutic portfolio, with the EnligHTN™ renal denervation system, elevates the standard of patient care by leveraging the latest advances in cardiac ablation technology and applying them to renal denervation.

Remote Monitoring Portfolio

Our remote monitoring portfolio, with Merlin.net™ Patient Care Network and Merlin@home™ wireless transmitter can help you optimize workflow, support informed clinical decisions and deliver efficient, comprehensive care.

Hypertension affects 1 in 3 adults wordwide

Technology to Better Treat Resistant Hypertension

Renal denervation is a catheter-based ablation procedure used to treat patients with drug-resistant hypertension. The EnligHTN™ renal denervation system administers simultaneous lesions that disrupt renal nerve activity and deliver a rapid, significant and sustained reduction in blood pressure.7

Learn about hypertension management.

MultiPoint™ pacing enables more tissue capture for better intraventricular conduction.7-9

More Options and Greater Control to Make Non-Response a Non-Issue

Our MultiPoint™ pacing products build upon the industry’s leading quadripolar technology by enabling you to pace the left ventricle from multiple locations on a single Quartet™ LV lead. MultiPoint pacing technology enables more tissue capture for better intraventricular conduction that leads to improved contractility.7-9

  • The Quadra Assura MP™ CRT-D and Quartet™ quadripolar LV pacing lead feature four pacing electrodes and 10 pacing vectors to provide more options and great control to address implant complications including diaphragmatic stimulation and high pacing thresholds.
  • The Quadra Allura MP™ RF CRT-P and Quartet™ quadripolar LV pacing lead feature four pacing electrodes and 14 pacing vectors to provide more options and greater control to address complications at and post implant to improve CRT response.

Clinical Leadership in HF Quality of Life and Overall Survival8,9

Our vision is to transform the treatment of expensive epidemic diseases, including heart failure, by creating innovative technologies that are clinically effective for patients and cost effective for hospitals. We back our innovation with clinical leadership by building a body of evidence that supports the improved outcomes and exceptional quality of our first-to-market therapies.

See Clinical Evidence

Physicians looking at a clipboard


1. Cook, C., Cole, G., Asaria, P., Jabhour, R., & Francis, D. (2013). The annual global economic burden of heart failure. Journal of the American College of Cardiology, 171, 368-376. http://dx.doi.org/10.1016/j.ijcard.2013.12.028
2. Ponikowski, P., Anker, S. D., AlHabib, K. F., Cowie, M. R., Force, T. L., Hu. S., … Filippatos, G. (2014). Heart failure: Preventing disease and death worldwide. ESC Heart Failure, 1(1), 4-25. http://dx.doi.org/10.1002/ehf2.12005
3. Neumann, T., Biermann, J., Erbel, R., Neumann, A., Wasem, J., Ertl, G., & Dietz, R. (2009). Heart failure: The commonest reason for hospital admission in Germany: Medical and economic perspectives. Deutsches Ärzteblatt International, 106(16), 269-275. http://dx.doi.org/10.3238/arztebl.2009.0269
4. World Health Organization. (2009). Global Health Risks: Mortality and Burden of Disease Attributable to Selected Major Risks. Retrieved from http://www.who.int/healthinfo/global_burden_disease/GlobalHealthRisks_report_full.pdf
5. Persell, S. D. (2011). Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension, 57(6), 1076–1080. http://dx.doi.org/10.1161/HYPERTENSIONAHA.111.170308
6. Schlaich,, M. P., Lambert, E., Kaye, D. M., Krozowski, Z., Campbell, D. J., Lambert, G., …  Esler, M. D. (2004). Sympathetic augmentation in hypertension: Role of nerve firing, norepinephrine reuptake, and angiotensin neuromodulation. Hypertension, 43(2), 169-175. http://dx.doi.org/10.1161/01.HYP.0000103160.35395.9E
7. Anand, I. S., Carson, P., Galle, E., Song, R., Boehner, J., Ghali, J. K., … Bristow, M. R., (2009). Cardiac resynchronization therapy reduces the risk of hospitalizations in patients with advanced heart failure: Results from the Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure (COMPANION) trial. Circulation, 119(7), 969-77. http://dx.doi.org/10.1161/CIRCULATIONAHA.108.793273
8. ACC NCDR ICD Registry data presented at St. Jude Medical 2013 Annual Investor Meeting, Friday, Feb. 1, 2013.
9. Corbisiero, R., Armbruster, R., & Muller, D. (2014, May). Reduced costs post CRT with quadripolar LV leads compared to bipolar LV leads. Presented at the meeting of the Heart Rhythm Society, San Francisco, CA.

Orange 24 surrounded by headset, represents "Place an order"

Contact Customer Service

Our customer service experts can help with your product orders or questions.